Antigenic relationships of simian virus 41 (SV41) to other paramyxoviruses were examined by immunoprecipitation of isotope-labelled SV41-infected cell lysates with specific antisera. SV41 is closely related to the group comprising human parainfluenza virus 2 (HPIV-2), simian virus 5 (SV5), parainfluenza virus 4 and mumps virus. Slight cross-neutralization was detected between SV41, HPIV-2 and SV5. Anti-SV41 activities were detected in 21 of 1116 human serum specimens, indicating that a proportion of the human population is infected with SV41. The haemagglutinin-neuraminidase of SV41 was preferentially immunoprecipitated by anti-SV41 positive sera.
Introduction
The paramyxovirus simian virus 41 (SV41) was originally isolated from cynomolgus monkey kidney cell cultures. The agent was thought not to be widespread in human populations (Miller et al., 1964) . However, simian virus 5 (SV5), which was also isolated from monkey tissues (Hull et al., 1956) , has been isolated from a number of human populations, and the virus antigens can be detected directly in bone marrow (Hsiung, 1972) . Accordingly, there is a possibility that SV41 may be infectious to human populations. In this study, we performed serological analyses of human sera and obtained some evidence of infection of human populations with SV41.
Methods
Viruses and cells. The viruses used in this study were SV41 (strain Chanock), human parainfluenza virus type 2 (HPIV-2, strain Toshiba) and SV5 (strain 21004-WR). These viruses were propagated in primary monkey kidney (PMK) cells, which were grown in Eagle's minimum essential medium (MEM) supplemented with 5~ foetal calf serum. Vero cells were used for neutralization tests.
Human sera. Human sera tested in this study were kindly donated by Dr K. Shimokata, Nagoya University School of Medicine, and Dr M. Ito, Mie University School of Medicine. Healthy sera, post-vaccination sera and sera from the acute and convalescent phase of febrile upper respiratory tract infections, were included in these tests.
Serological tests.
For screening anti-SV41 positive serum, a haemadsorption inhibition assay was employed. PMK cells were inoculated with approximately 100 p.f.u, of virus and, 2 days after inoculation, the virus-infected cells were preincubated with fourfold-diluted human 0000-9562 © 1990 SGM serum for 2 h. Subsequently, 100 Ixl of 1~ guinea-pig blood cell suspension was added to the cell cultures, the cells were left for 1 h at room temperature and were then washed four times with Eagle's MEM. Haemadsorption inhibition was judged by microscopic observation. Neutralization tests were performed by assaying for plaque reduction; titres were expressed as the reciprocal of the highest serum dilution causing 50~ reduction of plaque counts. Human sera were preincubated at 56 °C for 30 min, and a twofold dilution series was mixed with an equal volume of virus preparation. The concentration of the virus was adjusted to give 60 to 70 p.f.u, per well. The mixture was incubated at 37 °C for 1 h and inoculated onto Vero cell monolayers. Plaques were counted 5 days after inoculation.
Antisera. Antisera against the various paramyxoviruses used in this study are listed in Table 1 . In addition, four normal rabbit sera, designated 0-1, 0-2, 0-3 and 0-4, were used as controls.
Radioimmunoprecipitation and SDS PAGE. Isotopic labelling of the virus-infected cells, immunoprecipitation and SDS-PAGE were carried out according to methods described previously (Ito et al., 1987) .
Results

Reactivities of antisera against various paramyxoviruses with SV41-infected cell lysates
A total of 28 antisera against 11 paramyxoviruses [SV41, HPIV-1, HPIV-2, HPIV-3, HPIV-4A, HPIV-4B, SV5, mumps virus (MuV), Sendai virus (SV), Newcastle disease virus (NDV) and measles virus (MV)] were tested for reactivity with SV41. This was assessed by the immunoprecipitation reaction, using [35S]methioninelabelled extracts of SV41-infected cells. These sera reacted strongly with homologous viruses in this assay system (Ito et al., 1987) . Since the nucleoprotein (NP) Table 2 . Antisera against H P I V -2 i m m u n o p r e c i p i t a t e d SV41 haema g g l u t i n i n -n e u r a m i n i d a s e ( H N ) and N P , and antisera against M u V or SV5 react weakly with H N a n d / o r NP. Intriguingly, one (4-4) of four sera against H P I V -4 A reacted distinctly with the H N and N P of SV41, but no reactivity of the other three sera with these proteins was detected. To prepare the 4-4 serum, a m o n k e y was intranasally inoculated twice with infective H P I V -4 A whereas 4-1, 4-2 and 4-3 antisera were o b t a i n e d from rabbits m u l t i -i m m u n i z e d with H P I V -4 A and F r e u n d ' s complete adjuvant. Thus, one possibility is that natural infection with H P I V -4 A m a y be a r e q u i r e m e n t for the induction of antibodies which cross-react with SV41. In a previous study (Ito et al., 1987) , it was found that SV, HPIV-1 and H P I V -3 belonged to one antigenic group, and that HPIV-2, HPIV-4, M u V and SV5 belonged to a second group. Thus, SV41 is closely related to the second antigenic group. Since the h u m a n paramyxoviruses, HPIV-1, -2, -3, -4 and MuV, formed a single antigenic group which o v e r l a p p e d the above groups, it was not unexpected that the H N and N P proteins of SV41 were weakly i m m u n o p r e c i p i t a t e d with one of two a n t i -H P I V -3 antisera. Interestingly, anti-MV antiserum reacted with the N P of SV41 (Fig. 1) . This is the first time that antigenic cross-reactivity between a p a r a m y x o v i r u s and a morbillivirus has been demonstrated. Next, the interrelationships between SV41, H P I V -2 and SV5 were investigated. R e p r e s e n t a t i v e a u t o r a d i o g r a m s and a s u m m a r y are presented in Fig. 2 and Table 3 , respectively. Although homologous reactions were stronger t h a n heterologous reactions, the three viruses showed close inter-relationships. 
Detection of anti-SV41 antibody activities in human sera
At first, cross-reactions of sera from animals hyperimmunized with SV41, HPIV-2 and SV5 were examined using plaque reduction. Although slight cross-reactivity of heterologous viruses with heterologous antisera was detected, homologous inhibition was at least 16-fold greater than heterologous inhibition (Table 4) . Plaque reduction neutralization tests could therefore be used to prove the existence of virus-specific antibody. Using the haemadsorption inhibition method, 1116 specimens of human serum were screened for anti-SV41 antibody activity and 146 specimens (about 13 %) were found to be positive. Subsequently, the positive sera were incubated at 56 °C for 30 min and then tested for neutralizing activity against SV41, HPIV-2 or SV5. As shown in Table 5 , 40 specimens neutralized at least one of the viruses. These specimens were divided into three groups: the 10 sera in which anti-SV41 titres were highest were designated group I; group II consisted of those sera whose anti-SV41 activity was lower than the titre of either anti-SV5 or anti-HPIV-2 activity; sera belonging to group III showed anti-SV5 and/or anti-HPIV-2 activity, but less than 4 units of anti-SV41 titre. In 11 of the 17 sera belonging to group II, titres of anti-SV41 activity were not less than one-fourth of the titre against the other viruses activity; these sera were designated IIa and the remainder lib. Therefore, it is reasonable to SV41  SV5  HPIV-2   IIa   41-6F  256  64  <4  IIb  N36-2G  128  32  4  40-81  64  16  <4  40-4G  64  16  64  42-7F  64  32  32  42-5G  32  8  16  40-6B  32  16  <4  42-6E  16  <4  16  III  N31-6G  8  <4  4  N35-1H  8  <4  <4   N34-5E  1024  2048  <4  N31-8D  256  512  64  43-7G  128  512  8  28-10G  64  128  <4  87  32  128  16  42-4F  32  128  4  42-2E  32  64  16  42-7E  32  64  32  42-5E  16  64  16  88  16  64  16  N35-8F  8  16  <4   28-10E  128  2048  16  42-5H  64  512  4  42-3H  32  512  4  41-8D  32  512  32  42-4E  16  128  32  42-3E  8  64  8   N33-6I  4  16  16  N35-5D  4  16  16  N35-9A  <4  8  <4  N36-10J  <4  8  8 conclude that at least 21 of the 1116 human specimens examined have been infected with SV41.
Immunoprecipitation of 35S-labelled cell lysates infected with SV41, SV5 or HPIV-2 by human sera
To analyse specificities of the human sera in detail, immunoprecipitation was carried out. Five sera were selected, two belonging to group I, two to IIb and one to III. Two control human sera showing no antibody activity and hyperimmune sera against SV41, SV5 or HPIV-2 were included. 41-6F and 40-8I, belonging to group I, immunoprecipitated the HN of SV41, but not that of SV5 or HPIV-2 (Fig. 2) . 28-10E and 41-8D, belonging to group IIb, showed antibody activity against the HN of SV41, SV5 and HPIV-2, and precipitated the HN of SV41. Since the hyperimmune serum against SV5 or HPIV-2 hardly precipitated the HN of SV41 under these conditions, these four sera were thought to contain antibody against the HN of SV41. On the other hand, N35-5D, belonging to group III, precipitated the HN of HPIV-2, but not the HN of SV41. Furthermore, six sera showing anti-SV41 neutralizing activity were analysed using the immunoprecipitation method. As shown in Fig. 3 , the HN of SV41 was preferentially precipitated by these sera.
Discussion
Human paramyxoviruses have been divided into two groups; HPIV-1 and HPIV-3 belong to one group and HPIV-2, HPIV-4 and MuV belong to the other group (Ito et al., 1987; Komada et al., 1989; Tsurudome et al., 1989; Kondo et al., 1990; Kawano et al., 1990) . In this study, SV41 was found to belong to the latter group, and HPIV-2, SV5 and SV41 form the parainfluenza type 2 group. SV5 was originally detected in monkey tissues and has never been associated with any human disease (Hull et al., 1956) . However, it has been isolated from a number of human sources, including the bone marrow and cerebrospinal fluid of multiple sclerosis patients (Goswami & Russell, 1982; Goswami et al. 1987) . Goswami et al. (1984) reported that about 20% of individuals in London were found by serological studies to be infected with SV5. SV41 was also detected and isolated from cultures of monkey tissues (Hull et al., 1958; Miller et al., 1964) . Miller et al., reported that a pool of human gamma globulin did not neutralize SV41, suggesting that the agent was not widespread in the human population. In this study, a large number of human sera were tested to attempt to detect anti-SV41 specific activity. Of a total of 1116 specimens, 21 (2.0%) proved almost certainly to have anti-SV41 antibody, indicating that SV41 is infectious to human populations.
Some of the problems to be solved are isolation of SV41 from human populations, determination of the actual extent of its prevalence in human populations and the relationship of SV41 infection to human diseases. These investigations are in progress in our laboratory.
